Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Salvarx Group Plc LSE:SALV London Ordinary Share IM00BZ4SS228 ORD 2.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 4.50 0.00 0.00 0.00 0.00 - 0.00 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.0 -0.5 1.0 4.5 2

Salvarx Share Discussion Threads

Showing 301 to 323 of 500 messages
Chat Pages: 20  19  18  17  16  15  14  13  12  11  10  9  Older
DateSubjectAuthorDiscuss
22/8/2018
08:18
Also Dex, before we get ahead of ourselves, there is competition... https://dailym.ai/2Bu6RO4
fig1
22/8/2018
07:59
Good god. What did they say in the prior tweet that could possibly have left the door open to that interpretation such that a clarification was necessary ? Summary: Tweet one - good news a patient has survived six years using drugs Tweet two - just to be clear, they weren't our drugs, they were someone else's drugs that are clearly working thus rendering our drugs potentially redundant Great. Well done.
dexdringle
21/8/2018
22:20
This is a nice story but I hope the person responsible for tweeting at Intensity leaves out the whimsy and sticks to facts pertaining to relevant trials. This is just damaging potentially. https://twitter.com/IntensityInc/status/1031993192349032448?s=19
fig1
21/8/2018
17:26
About to take off soon. Doing a deal when it's quiet in August. Expect big news and interest during September. I can see Portage shares doing very well as those who benefited from the $200m+ pay out previously realise these guys are going for a repeat if not a bigger better deal having demonstrated their understanding of this sector before
the stigologist
21/8/2018
16:18
Oh, there we go. Pressure building.....
fig1
21/8/2018
08:52
I look forward to your contribution to the discussion. It is clear that between Mellon and Bailey they will end up with total control of Portage post deal, it is good of you to crunch the figures to confirm that. At least you are beginning to realise that it is the ordinary PIs invested in Portage that are going to be the real deciders. Biohaven like deals come around once in a blue moon. Portage got a good deal when they bought into Biohaven ie they did not pay 5 times what another market thought it was worth. Some PIs will, as you say, blindly follow management. The independent valuation produces a range of valuations not a single definitive valuation as there is no way to value a company like SALV Ltd definitively. It will be interesting to read it when Portage publish it with the circular. Hopefully Portage will also give the detailed result of the vote, ie number of shares voted each way. If it is anything like UK votes only about 50% of those eligible to vote will vote. The 50% that do will care deeply enough one way or the other to act in the way PIs can if the vote does not go their way. The available data (perhaps you can find more) shows Portage is relatively illiquid and will therefore be significantly impacted by a relatively small number of shares traded. In your contribution to the discussion you might also want to consider why more SALV shares were sold than bought yesterday.
sweet karolina
21/8/2018
07:23
Juvenescence doesn't currently have a market listing as far as I know.
fig1
21/8/2018
00:11
Dear me you don’t give up do you with your nonsense. Keep an eye out tomorrow and I’ll tell you the exact % positions of Mellon and Bailey both pre and post Portage. Not your long winded opinion on what individual minority holders may or may not do. They will vote on the evidence presented to them by the independent company that has been asked to do this, they will also be guided by larger stakeholders such as Mellon and Bailey. Somehow I have a feeling that virtually all will look at what the company did with Biohaven (turning $7 million initial investment into $210 million in special dividend Biohaven shares) when making their decisions. What would you do faced with those facts?
jonesyboy 27
20/8/2018
22:27
Jonesy, Tackle the ball not the man in your next post and you might contribute something of value to the discussion. You said previously the Portage vote was a done deal because Mellon et al were majority shareholders. Individually they are minority shareholders of both companies and there was a question as to whether they could vote in the Portage minority shareholders vote, required by Canadian Securities Law. It has now been established, through research backed up by a posted link, that as interested parties they cannot take part in the vote and therefore it is not the foregone conclusion you claimed it was. Following that you have done nothing to back up your opinion that it is still "nailed on to go through". In order to do that you need to consider dispassionately what Portage minority, disinterested shareholders are likely to do. Some undoubtedly will blindly do as they are told. Some however will be less than impressed by their directors massively diluting them and radically altering the shareholder register by paying "Consideration Shares valued at approximately US$75.8 million, representing a premium of over 250% to the current market valuation of SalvaRx" (Top Highlight point of SALV's RNS). You also need to consider what impact a proportion of the minority shareholders', who do vote against but do not win the vote, shares hitting a relatively illiquid market as soon as the halt is lifted would have. All I have done is stimulate discussion, backed up with some analogies and some data, on the various key issues, like the Portage minority disinterested shareholders perspective, which should inform investing decisions in this instance. I have repeatedly pointed out that everyone needs to make their own depending on their own circumstances and position. I have not criticised anyone who has declared what their decision is, nor have I sought to alter them - they are all perfectly reasonable. Indeed an understanding of what a variety of people feel is much more useful in trying to judge how the market as a whole may react than a single entrenched, but unsupported view.
sweet karolina
20/8/2018
20:55
I’ll make the position we find ourselves in clear in my next post
jonesyboy 27
20/8/2018
20:30
Karolina has made her position clear. She does not hold and has no intention of buying yet is on here constantly telling us for example that Mellon and Bailey aren’t the majority shareholders in Salv. You can either put 2&2 together and work out her motive or you cannot. If you get the answer 3 then sell, if you can’t do the sum then sell.
jonesyboy 27
20/8/2018
17:56
Jones- you or someone mentioned Mr Munger If someone was countering an investor of a position he held as sweet is here, i think he would maybe take on board and reflect on the counter argument, maybe reject such arguments but not get in to an argument; sweet is entitled to her opinion, t his is a debating forum we know not what Sweets position or agenda is but does that matter ? It is human nature to look for arguments that enforce our belief in our positions, but it is the top investors that are able to take a balanced view and listen to both sides The position here is highly speculative as to how it goes either way, such is the nature of early stage biotech....
kristini2
20/8/2018
14:43
Portage looks to be fairly thinly traded - perhaps about $10k per day on average? Https://ycharts.com/companies/PTGEF/price It certainly would not take many disgruntled with the deal shareholders to sell to drive it to 5c or below. It will be interesting to see how many shares are voted against the deal, as that would give some indication of how many might hit the market on resumption of trading, assuming the deal does get through.
sweet karolina
20/8/2018
14:27
Hmmmm. It all feels a bit 'pie in the sky'. Massive share issue from Portage to then do a share exchange. They are paying a massive premium (on the face of it) presumably because that is the only way that SALV shareholders will even entertain accepting an exchange for foreign penny shares. If it was an established pharma buying it they'd be: a) paying cash b) paying nothing like the proposed figure Portage shares will probably re-open at US$0.05 each thus halving the value of the bid. Am holding (for now) - but only because I don't have such a large holding that a fall back to 30p is not an issue for me.
dexdringle
20/8/2018
13:55
It is interesting how different people, depending on their own position, can have very different views on valuation. I remember the QPP / SGH debacle. SGH claimed to have done the most extensive DD ever, a bunch of mug Aussies believed them (now suing in a class action). There were some QPP shareholders who voted against the deal, believing SGH were robbing them. There were others who bought SGH believing SGH were getting a bargain. UKOG with a Market Cap of over £100M (at just under 2p) has just bought more of HHDL which gives their stake an implied valuation of 0.3p per share and there are people holding and buying believing UKOG should rise to 3p on the news and blaming MM tricks as to why not. Early stage Biotechs are far more difficult to value than just about anything else. Jim Mellon did a similar related party transaction taking AIM listed Plethora (Premature ejaculation spray) into HKSE listed Regent Pacific. That might be a more useful analogy than QPP/SGH or UKOG.
sweet karolina
20/8/2018
13:23
Nailed on to go through
jonesyboy 27
20/8/2018
13:23
dex, That is a strong possibility. Pharmaventures produced a range of valuations, using a variety of techniques (obviously NAV P/E etc do not apply). It will be interesting to see those when Portage produce the circular to non interested shareholders. We already know what the AIM market was valuing it at before the deal was announced (leaked).
sweet karolina
20/8/2018
12:48
….I can see this all falling over and being called off......
dexdringle
20/8/2018
12:27
It’s not hard to understand this the minority SH will have to vote on the deal using the independent valuation provided by pharmaventures on July 23rd.
jonesyboy 27
20/8/2018
11:46
My reading of this is NO! Portage related party directors cannot vote: Https://www.lexology.com/library/detail.aspx?g=070f960c-59c8-4f91-ac31-12d58a1adb9f "approval of disinterested security holders (i.e. the “majority of the minority” vote);" Everyone needs to form their own opinion on what way disinterested holders might vote and what the impact of a no vote would be and what those who voted no and were out voted would do with their shares (ie will they vote with their feet when then can) and what would be the impact of that both before completion of the deal and after. The beauty of being impartial is I can look at it from SALV and Portage PI perspectives. I have given my views on what I would do, but everyone has their own way of looking at things and will act on the basis of their own situation. Ultimately you need to think about what the overall market will do not just what you would do.
sweet karolina
20/8/2018
07:20
Back to personal attacks always a sure sign that people have something to hide. Can the related party directors of Portage vote their shares or not. A simple enough question which nobody wants to answer.
sweet karolina
19/8/2018
20:56
Having looked at Maple v Schneider I get the impression both were Canadian domiciled, which isn't the case here and this would involve expensive cross-border problems.. I suspect that as long as NED has no shares his view would be the defining factor from UK Courts/authorities perspective. Tax treatment is going to be defining factor for me.
bscuit
19/8/2018
19:23
I’ve just answered your question that you’ve asked again...you’ll be saying Mellon and Bailey aren’t the majority shareholders in both again. This is a hard fact that you still haven’t acknowledged. Yes I’ve read about a lot about minority shareholder protections in Canada. Maple Leaves Foods v Schneider Corp 1998 a classic example. You should maybe concentrate on shares you are actually invested in rather than something you’ve had a glance at...
jonesyboy 27
Chat Pages: 20  19  18  17  16  15  14  13  12  11  10  9  Older
ADVFN Advertorial
Your Recent History
LSE
SALV
Salvarx
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200812 11:42:21